China Clinical Nutrition for Cancer Care Market Report 2023 to 2030

China Clinical Nutrition for Cancer Care Market Analysis

$ 3999

The China Clinical Nutrition for Cancer Care Market was valued at $452.6 Mn in 2023 and is predicted to grow at a CAGR of 6.54% from 2023 to 2030, to $705.2 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, increasing risk of malnutrition in oncology patients, and advancements in nutritional products. The prominent players of the China Clinical Nutrition for Cancer Care Market are MediFood, Nestlé Health Science, Abbott Nutrition, B. Braun Melsungen AG, and Fresenius Kabi, among others.

ID: IN10CNPH565 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Aarti Patel

Buy Now

China Clinical Nutrition for Cancer Care Market Executive Summary

The China Clinical Nutrition for Cancer Care Market was valued at $452.6 Mn in 2023 and is predicted to grow at a CAGR of 6.54% from 2023 to 2030, to $705.2 Mn by 2030.

Clinical nutrition for cancer care is a specialized field focusing on providing optimal nutritional support to patients throughout their cancer journey. It goes beyond simply “eating healthy” and involves a personalized approach to address the unique nutritional needs of each patient. A registered dietitian or other qualified healthcare professional usually assess the patient’s nutritional status. Based on the assessment, a personalized plan is created to meet the patient’s individual needs. Nutritional deficiencies are prevalent among cancer patients due to treatment side effects, altered metabolism, and decreased appetite. Clinical nutrition interventions play a crucial role in improving treatment tolerance as adequate nutrition can help patients tolerate chemotherapy and radiation therapy better, potentially reducing side effects and allowing for completion of treatment plans. Also, it maintains strength and immunity as proper nutrition helps patients maintain muscle mass, fight infections, and recover faster from surgery. Lastly, it enhances the quality of life since nutritional support can improve fatigue, appetite, and overall well-being, leading to a better quality of life during cancer treatment.

Advancements in medical nutrition therapy have led to the development of specialized oral nutritional supplements (ONS) and enteral feeding formulas. These products provide concentrated nutrients and can be crucial for patients struggling to meet their nutritional needs through regular diet alone. Parenteral nutrition remains an option for patients unable to tolerate oral or enteral feeding. Overall, clinical nutrition for cancer care plays a vital role in optimizing patient outcomes by ensuring they receive the necessary nutrients to support their body throughout treatment.

The China Clinical Nutrition for Cancer Care Markets is driven by significant factors such as the increasing prevalence of cancer, increasing risk of malnutrition in oncology patients, and advancements in nutritional products. However, reimbursement policies, lack of awareness, and challenges in implementation restrict the growth and potential of the market.

The major players of the China Clinical Nutrition for Cancer Care Market are MediFood, Nestlé Health Science, Abbott Nutrition, B. Braun Melsungen AG, and Fresenius Kabi, among others.

China Clinical Nutrition for Cancer Care Market Report 023 to 2030

Market Dynamics

Market Growth Drivers

Increasing Prevalence of Cancer: A major driver for this market is the increasing global burden of cancer and the high mortality rates associated with it. As the population ages and lifestyle risks like smoking persist, the number of new cancer cases diagnosed each year continues to rise. According to the National Cancer Center (NCC) of China, in 2022, there were approximately 4.8 Mn new cancer cases in China with an age-standardized incidence rate of Chinese population (ASIR) of 208.58 per 100,000. This translates to a larger patient population requiring specialized nutritional support during treatment, which in turn drives the Clinical Nutrition for Cancer Care Market further.

Increasing risk of malnutrition in oncology patients: Malnutrition is a prevalent issue among cancer patients, caused by the disease itself and its treatment side effects such as reduced appetite, nausea, vomiting, diarrhoea, difficulty swallowing. As per the National Cancer Institute, 30% to 85% of cancer patients experience malnourishment during their treatment process. As the risk of malnutrition rises, there’s a corresponding increase in the demand for specialized nutritional support products and services. Thus, the demand increases the Clinical Nutrition for Cancer Care Market.

Advancements in nutritional products: The advancements provide healthcare professionals with a wider range of tools to address the diverse needs of cancer patients. The market is witnessing a surge in the development of immuno-nutrition solutions tailored to bolster the immune system of cancer patients, potentially enhancing treatment efficacy and reducing complications. Incorporating nutrigenomics into clinical nutrition approaches allows for personalized dietary recommendations based on an individual’s genetic makeup, potentially optimizing treatment response and minimizing adverse effects. These developments in nutrition ultimately lead to an expansion in the Clinical Nutrition for Cancer Care Market.

Market Restraints

Varied reimbursement policies: Reimbursement policies for nutritional support products like oral nutritional supplements (ONS) and enteral feeding formulas differ significantly across regions and even within healthcare systems. This can create access disparities for patients, particularly in areas with limited coverage or complex procedures for reimbursement. Thus, due to cost and reimbursement issues, the Clinical Nutrition for Cancer Care Market might not grow to its full potential.

Limited Awareness: While awareness is increasing, not all healthcare professionals may fully understand the significance of clinical nutrition in cancer care. This can lead to underutilization of nutritional support services and a failure to identify patients who could benefit from them. Some patients might not be fully aware of the benefits of proper nutrition during cancer treatment and the available support options. Therefore, the limited awareness can prevent the Clinical Nutrition for Cancer Care Market from growing.

Challenges in Implementation: The trend towards personalized nutrition plans requires adequate resources and support systems to effectively implement these plans for each patient after consideration of many factors. Also, seamlessly integrating clinical nutrition services into existing healthcare workflows can be challenging. This might require changes in practice patterns and fostering collaboration among different healthcare professionals. These changes in the healthcare structure can be hard to incorporate thus acting as a restraint for the Clinical Nutrition for Cancer Care Market.

Regulatory Landscape and Reimbursement Scenario

China’s pharmaceutical regulatory authority was previously called China Food and Drug Administration (CFDA) which was renamed to National Medicinal Products Administration (NMPA) in 2018. The NMPA is the government agency which is responsible for regulating the pharmaceuticals, cosmetics, medical devices, and in-vitro diagnostics in the nation.

The effectiveness and safety of medications, medical equipment, and cosmetics sold in China are ensured by the NMPA. This entails checking applications, carrying out examinations, and monitoring post-market risks. Also, the whole medical product life cycle, from research and development to manufacture, marketing, and distribution, is governed by rules that are created and enforced by the NMPA. The Chinese Pharmacopoeia, which establishes quality standards for pharmaceuticals, is one of the requirements they set for the safety and quality of medicinal products. By expediting the approval procedures for cutting-edge medications and equipment, the NMPA promotes research and development of new and improved medical products.

The NRDL is the main pathway for pharmaceutical reimbursement in China, with primary goal being to improve affordability of drug treatments. The reimbursement landscape for pharmaceuticals in China is complex and prioritizes cost-effectiveness. Even though there are several advantages to being an NRDL member, there are competition in the process and significant cost savings. It is essential for pharmaceutical companies doing business in China to comprehend this framework.

Competitive Landscape

Key Players

Here are some of the major key players in the China Clinical Nutrition for Cancer Care Market:

MediFood
Nestlé Health Science
Abbott Nutrition
B. Braun Melsungen AG
Fresenius Kabi
Danone Nutrica
Baxter International Inc.
Victus Inc.
Mead Johnson
Aymes

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

China Clinical Nutrition for Cancer Care Market Segmentation

By Type

Oral Nutrition
Parenteral Nutrition
Enteral Feeding Formulas

By Cancer Type

Head & Neck Cancer
Stomach & Gastrointestinal Cancer
Blood Cancer
Breast Cancer
Lung Cancer
Others

By Age Group

Adult
Paediatric

By Sales Channel

Offline
Online

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.